Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, namely statins, exert pleiotropic actions beyond lipid-lowering effects. Their pharmacological activity on atherosclerotic plaque stability and vascular inflammation appears to be mediated, at least in part, by nitric oxide (NO). With the aim of enhancing the nonlipid-lowering properties of selected statins, we introduced a NO-releasing moiety into the structure of pravastatin (NCX 6550) and fluvastatin (NCX 6553). NO release was evaluated as nitrosylhemoglobin adduct formation by using EPR spectroscopy in rat blood. Both compounds produced a linear time-dependent increase in nitrosylhemoglobin formation, which is consistent with slow NO release kinetics. In PC12 cells, unlike their native statins, both compounds stimulated cGMP formation (NCX 6550, EC 50= 2.3 ± 0.2 μM; NCX 6553, EC 50= 2.7 ± 0.2 μM). Moreover, NCX 6550 potently inhibited cell proliferation in rat aortic smooth muscle cells (IC 50= 2.2 ± 0.3 μM) with a mechanism that involved both the polyamine and HMG-CoA reductase signaling pathways. Hence, mevalonate or putrescine partially reverted the effects of NCX 6550 and their combination was fully effective. In RAW 264.7 murine macrophage cells stimulated with lipopolysaccharide (1 μg/ml), NCX 6550, but not pravastatin, significantly decreased inducible NO synthase and cyclooxygenase-2 protein expression as well as nitrite accumulation. All together, the data show that the previously undescribed NO-releasing statins retain HMG-CoA reductase inhibitory activity and release bioactive NO slowly. Among the additional properties, compared with native statins, the NO-releasing statins show enhanced antiinflammatory effects. Thus, NO-releasing statins represent an interesting class of drugs having potential in the therapy of disorders associated with endothelial dysfunction and vascular inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035
The macrophage foam cell as a target for therapeutic intervention
Li, A. C., & Glass, C. K. (2002) · Nature Medicine · doi:10.1038/nm1102-1235 · Cited by 700
Heart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(11)61125-2 · Cited by 373
Cited by
Recent developments in nitric oxide donor drugs
Miller, M. R., & Megson, I. L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707224 · Cited by 628
Nitric oxide and atherosclerosis: An update
Napoli, C., de Nigris, F., Williams-Ignarro, S., Pignalosa, O., Sica, V., & Ignarro, L. J. (2006) · Nitric Oxide · doi:10.1016/j.niox.2006.03.011 · Cited by 463
Self-citationCyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Tsai, E. J., & Kass, D. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.009 · Cited by 420
Cholesterol in Alzheimer's disease
Shobab, L. A., Hsiung, G.-Y. R., & Feldman, H. H. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70248-9 · Cited by 336
Chen, K., Pittman, R. N., & Popel, A. S. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1959 · Cited by 326
Metadata
- Authors
- Ongini, E., Impagnatiello, F., Bonazzi, A., Guzzetta, M., Govoni, M., Monopoli, A., Del Soldato, P., & Ignarro, L. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-06
- Volume
- 101
- Issue
- 22
- Pages
- 8497-8502
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1978869728
- Cited by
- 101
- References
- 4
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.